ReviewPatient preference and adherence2018

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol.

Antonio Molino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.